GM1 Ganglioside Injection for Parkinson's Motor Fluctuations
Part of Brain & nervous system clinical trials.
This study tests whether an injection of a naturally occurring nerve-protective substance called GM1 ganglioside can reduce motor fluctuations (sudden off-periods and unpredictable movement changes) in people with Parkinson's disease who take levodopa. The goal is to help smooth out medication effectiveness throughout the day.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 30 or older at screening
- Confirmed diagnosis of Parkinson's disease (not Parkinson-plus variants)
- Currently taking levodopa at a stable dose of at least 400 mg per day for at least 4 weeks, and experiencing motor fluctuations (wearing off or on-off periods)
- Moderate to advanced Parkinson's stage (Hoehn-Yahr stage 2 or higher when medication wears off)
- No dementia or severe cognitive impairment
- No history of other neurological diseases, autoimmune diseases, or demyelinating diseases
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new medication called Lu AF28996 to help reduce the periods when Parkinson's symptoms worsen throughout the day (called 'OFF times'). If you have motor fluctuations that are predictable and affecting your daily life, this study might help you experience fewer of these difficult periods.
This trial tests a new injection called UX-DA003 for people with Parkinson's disease whose current medications are becoming less effective. It aims to see if this treatment can help reduce "off" time and improve motor symptoms.
This trial tests an injection called XS411CN for people with Parkinson's disease whose current medications are not working as well as before. The goal is to see if it is safe and tolerable.
This trial tests a new experimental drug called ALN-SNCA, given as an injection into the spinal fluid, for people with early Parkinson's disease. The goal is to see if it is safe and well-tolerated.
This trial tests an investigational gene therapy injection called GM101 for people with advanced Parkinson's disease whose symptoms are not well controlled by standard medications. The study will see if this treatment can help improve movement and quality of life.
This study tests a new gene therapy called LY-N001, which is injected directly into the brain. It is for people with moderate to advanced Parkinson's disease who have a specific genetic change in the GBA1 gene. The goal is to see if this treatment is safe and can help improve symptoms.
Hear when a new Parkinson’s disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.